drugset / Trial / NCT00436527

Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application

NCT00436527 ↗

Phase 4 Completed 26 enrolled Galderma R&D
RandomizedSingle-groupSingle-blindTreatment

Summary

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.

Timeline

Start
2006-08
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Metronidazole Small molecule 1 % Topical

Indications